Effects of tenascin-C on normal and diabetic retinal endothelial cells in culture.

PURPOSE Tenascin-C (TN-C) is expressed in embryogenesis, tissue remodeling, and healing. It is up-regulated in retinas of patients affected by diabetic retinopathy (DR). Because TN-C may promote neovascularization, its potential angiogenic effects were examined in vitro in normal and diabetic retinal endothelial cells (RECs). METHODS Bovine and human RECs were cultured on plastic or reconstituted basement membrane (BM) matrix. Production of TN-C, capillary-like tube formation, secondary sprouting, and cell migration, survival, and proliferation were measured with or without angiogenic growth factors (GFs). Antibodies and inhibitors were used to determine the involvement of specific TN-C receptors and signaling pathways. RESULTS TN-C significantly delayed collapse of REC capillary-like tubes on BM matrix. It decreased tube involution associated with serum deprivation, high glucose, and exposure to TGF-beta. TN-C's enhancement of tube stability was mediated by alphavbeta3 integrin. TN-C increased REC viability in 0.5% serum and stimulated REC proliferation in 10% serum. It promoted REC secondary sprouting on BM matrix, which involved signaling through mitogen-activated kinase kinase (MEK) and p38 mitogen-activated protein kinase. TN-C also enhanced tube branching after treatment with VEGF and stimulated REC migration twofold. Angiogenic GF increased TN-C production by RECs in an additive manner, which may explain higher levels of TN-C deposition in DR cells. CONCLUSIONS TN-C was overexpressed in diabetic and DR REC cultures. TN-C enhanced the sprouting, migratory, and survival effects of angiogenic GFs, and had distinct proliferative, migratory, and protective capacities. The data suggest that TN-C may act as a proangiogenic mediator in DR and other pathologic conditions involving neovascularization.

[1]  T. Ohnishi,et al.  Expression of tenascin in human gliomas: its relation to histological malignancy, tumor dedifferentiation and angiogenesis , 2004, Acta Neuropathologica.

[2]  Jeffrey C. Allen,et al.  Tenascin-C promotes microvascular cell migration and phosphorylation of focal adhesion kinase. , 2002, Cancer research.

[3]  D. Sheppard,et al.  The EIIIA Segment of Fibronectin Is a Ligand for Integrins α9β1 and α4β1Providing a Novel Mechanism for Regulating Cell Adhesion by Alternative Splicing* , 2002, The Journal of Biological Chemistry.

[4]  A. Ljubimov,et al.  Effects of angiogenic growth factor combinations on retinal endothelial cells. , 2002, Experimental eye research.

[5]  S. Majka,et al.  Regulation of matrix metalloproteinase expression by tumor necrosis factor in a murine model of retinal neovascularization. , 2002, Investigative ophthalmology & visual science.

[6]  K. Akassoglou,et al.  Plasmin-dependent and -independent effects of plasminogen activators and inhibitor-1 on ex vivo angiogenesis. , 2001, American journal of physiology. Heart and circulatory physiology.

[7]  S. H. Wilson,et al.  Modulation of retinal endothelial cell behaviour by insulin-like growth factor I and somatostatin analogues: implications for diabetic retinopathy. , 2001, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[8]  A. Faissner,et al.  The structure and function of tenascins in the nervous system. , 2001, Matrix biology : journal of the International Society for Matrix Biology.

[9]  A. Schor,et al.  Collagen gel assay for angiogenesis : induction of endothelial cell sprouting. , 2001, Methods in molecular medicine.

[10]  J. McCubrey,et al.  Kinases: positive and negative regulators of apoptosis , 2000, Leukemia.

[11]  S. Dallabrida,et al.  Expression of Antisense to Integrin Subunit β3Inhibits Microvascular Endothelial Cell Capillary Tube Formation in Fibrin* , 2000, The Journal of Biological Chemistry.

[12]  R. Davis,et al.  Signal Transduction by the JNK Group of MAP Kinases , 2000, Cell.

[13]  P. Campochiaro,et al.  Retinal and choroidal neovascularization , 2000, Journal of cellular physiology.

[14]  L. Aiello,et al.  Role of vascular endothelial growth factor in diabetic vascular complications. , 2000, Kidney international. Supplement.

[15]  Jae Min Kim,et al.  Expression of tenascin-C in astrocytic tumors: its relevance to proliferation and angiogenesis. , 2000, Surgical neurology.

[16]  J. Schwarzbauer,et al.  Tenascin-C Suppresses Rho Activation , 2000, The Journal of cell biology.

[17]  R. Simó,et al.  Hepatocyte growth factor in vitreous and serum from patients with proliferative diabetic retinopathy , 2000, The British journal of ophthalmology.

[18]  P. Jones,et al.  The tenascin family of ECM glycoproteins: Structure, function, and regulation during embryonic development and tissue remodeling , 2000, Developmental dynamics : an official publication of the American Association of Anatomists.

[19]  M. Tucci,et al.  Recombinant production of PIGF-1 and its activity in animal models. , 2000, Farmaco.

[20]  M. Brownlee,et al.  Negative consequences of glycation. , 2000, Metabolism: clinical and experimental.

[21]  P. Jones,et al.  Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. , 2000, The Journal of clinical investigation.

[22]  M. Derwahl,et al.  Increased levels of platelet-derived growth factor in vitreous fluid of patients with proliferative diabetic retinopathy. , 2000, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[23]  S. Werner,et al.  Glucocorticoid-regulated gene expression during cutaneous wound repair. , 2000, Vitamins and hormones.

[24]  Lois E. H. Smith,et al.  Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor , 1999, Nature Medicine.

[25]  A. Albini,et al.  In Vitro Models of Angiogenesis: The use of Matrigel , 1999, The International journal of biological markers.

[26]  S. Schenk,et al.  The fibrinogen globe of tenascin-C promotes basic fibroblast growth factor-induced endothelial cell elongation. , 1999, Molecular biology of the cell.

[27]  A. Ljubimov,et al.  Basement membrane and growth factor gene expression in normal and diabetic human retinas. , 1999, Current eye research.

[28]  P. Jones,et al.  Regression of hypertrophied rat pulmonary arteries in organ culture is associated with suppression of proteolytic activity, inhibition of tenascin-C, and smooth muscle cell apoptosis. , 1999, Circulation research.

[29]  H. Nishigori,et al.  ProMMP-9 (92 kDa gelatinase) in vitreous fluid of patients with proliferative diabetic retinopathy. , 1999, Life sciences.

[30]  L. Aiello,et al.  Molecular mechanisms of growth factor action in diabetic retinopathy , 1999 .

[31]  A. Das,et al.  Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor. , 1999, Archives of ophthalmology.

[32]  E. Dejuan,et al.  Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes. , 1999, Investigative ophthalmology & visual science.

[33]  M. Rabinovitch,et al.  Induction of vascular smooth muscle cell tenascin-C gene expression by denatured type I collagen is dependent upon a beta3 integrin-mediated mitogen-activated protein kinase pathway and a 122-base pair promoter element. , 1999, Journal of cell science.

[34]  R. Probstmeier,et al.  Tenascin-C inhibits beta1 integrin-dependent cell adhesion and neurite outgrowth on fibronectin by a disialoganglioside-mediated signaling mechanism. , 1999, Glycobiology.

[35]  R. Tarnuzzer,et al.  Matrix Metalloproteinase Expression in Human Retinal Microvascular Cells , 1998, Diabetes.

[36]  D. S. Mcleod,et al.  Adenosine stimulates canine retinal microvascular endothelial cell migration and tube formation. , 1998, Current eye research.

[37]  J. Handa,et al.  The advanced glycation endproduct pentosidine induces the expression of PDGF-B in human retinal pigment epithelial cells. , 1998, Experimental eye research.

[38]  M. Detmar,et al.  Angiogenesis promoted by vascular endothelial growth factor: regulation through alpha1beta1 and alpha2beta1 integrins. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[39]  J. Spranger,et al.  Growth Factor Alterations in Advanced Diabetic Retinopathy: A Possible Role of Blood Retina Barrier Breakdown , 1997, Diabetes.

[40]  T. Schulthess,et al.  Concerted action of tenascin-C domains in cell adhesion, anti-adhesion and promotion of neurite outgrowth. , 1997, Journal of cell science.

[41]  E. Ruoslahti,et al.  Integrins as signaling molecules and targets for tumor therapy. , 1997, Kidney international.

[42]  M. Mattson,et al.  Oxidative stress mediates monocrotaline-induced alterations in tenascin expression in pulmonary artery endothelial cells. , 1997, The international journal of biochemistry & cell biology.

[43]  P Massin,et al.  Growth factors and diabetic retinopathy. , 1997, Diabetes & metabolism.

[44]  M. Boulton,et al.  Intravitreal growth factors in proliferative diabetic retinopathy: correlation with neovascular activity and glycaemic management , 1997, The British journal of ophthalmology.

[45]  N. Hynes,et al.  Apoptosis is accompanied by changes in Bcl-2 and Bax expression, induced by loss of attachment, and inhibited by specific extracellular matrix proteins in mammary epithelial cells. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[46]  S. Baatout.  Endothelial differentiation using Matrigel (review). , 1997, Anticancer research.

[47]  A. Nesburn,et al.  Basement membrane abnormalities in human eyes with diabetic retinopathy. , 1996, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[48]  H. Hammes,et al.  Modification of vitronectin by advanced glycation alters functional properties in vitro and in the diabetic retina. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[49]  K. Crossin,et al.  Tenascin: A multifunctional extracellular matrix protein with a restricted distribution in development and disease , 1996, Journal of cellular biochemistry.

[50]  U. Bartsch.  The extracellular matrix molecule tenascin-C: Expression in vivo and functional characterization in vitro , 1996, Progress in Neurobiology.

[51]  David A. Cheresh,et al.  Definition of Two Angiogenic Pathways by Distinct αv Integrins , 1995, Science.

[52]  S. Schenk,et al.  The complexity in regulating the expression of tenascins , 1995, BioEssays : news and reviews in molecular, cellular and developmental biology.

[53]  B. Ballermann,et al.  Inhibition of Capillary Morphogenesis and Associated Apoptosis by Dominant Negative Mutant Transforming Growth Factor-β Receptors (*) , 1995, The Journal of Biological Chemistry.

[54]  M. Schachner,et al.  Recognition molecules myelin‐associated glycoprotein and tenascin‐C inhibit integrin‐mediated adhesion of neural cells to collagen , 1995, Journal of neuroscience research.

[55]  A. Canfield,et al.  Evidence that tenascin and thrombospondin-1 modulate sprouting of endothelial cells. , 1995, Journal of cell science.

[56]  J. Kinsella,et al.  Reorganization of endothelial cord‐like structures on basement membrane complex (Matrigel): Involvement of transforming growth factor β1 , 1994, Journal of cellular physiology.

[57]  H. Kleinman,et al.  Inhibitors of basement membrane collagen synthesis prevent endothelial cell alignment in matrigel in vitro and angiogenesis in vivo. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[58]  S. Rubin,et al.  Cloning and characterization of alternatively spliced isoforms of rat tenascin. Platelet-derived growth factor-BB markedly stimulates expression of spliced variants of tenascin mRNA in arterial smooth muscle cells. , 1994, The Journal of biological chemistry.

[59]  H. Kawakatsu,et al.  Tenascin induction in tenascin nonproducing carcinoma cell lines in vivo and by TGF‐β1 in vitro , 1994, Journal of cellular physiology.

[60]  R. Chiquet‐Ehrismann.  Tenascin and other adhesion-modulating proteins in cancer. , 1993, Seminars in cancer biology.

[61]  M. Bourdon,et al.  Endothelial cell attachment and spreading on human tenascin is mediated by alpha 2 beta 1 and alpha v beta 3 integrins. , 1993, Journal of cell science.

[62]  R. Tucker,et al.  Tenascin expression in the mouse: in situ localization and induction in vitro by bFGF. , 1993, Journal of cell science.

[63]  L. Mandarino.  Current Hypotheses for the Biochemical Basis of Diabetic Retinopathy , 1992, Diabetes Care.

[64]  J. Spring,et al.  Two contrary functions of tenascin: Dissection of the active sites by recombinant tenascin fragments , 1989, Cell.

[65]  R. Schleef,et al.  The effect of fibrin on endothelial cell migration in vitro. , 1982, Tissue & cell.